Integrated Historical Valuation

INBP -  USA Stock  

USD 1.09  0.03  2.83%

Some fundamental drivers such as market cap or Integrated Biopharma enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Integrated Biopharma valuation indicators such as Earnings before Tax of 7.8 M or Average Equity of 10.7 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Integrated Biopharma's future value. Financial Statement Analysis is much more than just reviewing and breaking down Integrated Biopharma prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Integrated Biopharma is a good buy for the upcoming year.
Please see Risk vs Return Analysis.

Integrated Historical Statements 


About Integrated Valuation Data Analysis

Valuation is the financial process of determining what Integrated Biopharma is worth. Integrated Biopharma valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Integrated Biopharma valuation ratios help investors to determine whether Integrated OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Integrated with respect to the benefits of owning Integrated Biopharma security.

Integrated Biopharma Valuation Data Chart

Integrated valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Integrated equity instrument and the benefits of owning shares of Integrated Biopharma.
Integrated Biopharma Working Capital is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Working Capital of 8.76 Million

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from Total Assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Integrated Biopharma theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Integrated Biopharma debt, but would also pocket its cash. Enterprise Value is more accurate representation of Integrated Biopharma value than its market capitalization because it takes into account all of Integrated Biopharma existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

Market Capitalization

Market capitalization (or market cap) is the total value of the shares outstanding of Integrated Biopharma. It is equal to Integrated Biopharma current share price times the number of Integrated Biopharma outstanding shares. Represents the product of [SharesBas]; [Price] and [ShareFactor].
Most indicators from Integrated Biopharma valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into Integrated Biopharma current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Integrated Biopharma Working Capital is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Working Capital of 8.76 Million
 2018 2019 2020 2021 (projected)
Invested Capital Average17.58 M18.53 M20.21 M20.89 M
Invested Capital19.86 M20.58 M21.99 M21.9 M

Integrated Biopharma valuation accounts Correlations

Integrated Biopharma Account Relationship Matchups

Integrated Biopharma valuation accounts Accounts

201620172018201920202021 (projected)
Average Assets14.61 M14.55 M21.08 M20.8 M25.37 M23.96 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings Before Interest Taxes and Depreciation Amortization USD3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings before Tax1.86 M1 M2.04 M3.09 M7.25 M7.82 M
Average Equity(7.2 M)(5.96 M)985.75 K3.91 M9.91 M10.69 M
Enterprise Value18.4 M17.26 M16.52 M21.91 M40.83 M34.28 M
Free Cash Flow70 K927 K(86 K)1.13 M2.75 M2.97 M
Invested Capital19.17 M12.72 M19.86 M20.58 M21.99 M21.9 M
Invested Capital Average18.29 M16.28 M17.58 M18.53 M20.21 M20.89 M
Market Capitalization4.01 M3.17 M6.8 M13.3 M32.75 M35.33 M
Tangible Asset Value15.2 M14.57 M19.79 M22.94 M25.44 M23.54 M
Working Capital1.4 M(3.92 M)1.73 M3.36 M8.76 M9.45 M

Integrated Biopharma Investors Sentiment

The influence of Integrated Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Integrated. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - INBP

Integrated Biopharma Investor Sentiment

Most of Macroaxis users are currently bullish on Integrated Biopharma. What is your judgment towards investing in Integrated Biopharma? Are you bullish or bearish?
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Integrated Biopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.